Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Iressa Approval Would Set Bad Precedent For Oncology, Genta CEO Tells BIO

Executive Summary

FDA's decision about AstraZeneca's pending oncologic Iressa will send a "strong message" to industry about whether the agency is serious about high approval standards for cancer drugs, Genta CEO Ray Warrell, MD, said Feb. 26 during the Biotechnology Industry Organization CEO and investor conference in New York

You may also be interested in...



Iressa Gets Narrowed Indication Instead Of Withdrawal: New Model For FDA?

FDA's decision to narrow the indication for AstraZeneca's Iressa rather than withdraw the drug could be seen as a model for future products approved under Subpart H that fail in confirmatory trials

Iressa Gets Narrowed Indication Instead Of Withdrawal: New Model For FDA?

FDA's decision to narrow the indication for AstraZeneca's Iressa rather than withdraw the drug could be seen as a model for future products approved under Subpart H that fail in confirmatory trials

Iressa To The Rescue: Oncology Stocks Stand Out On Wall Street

Millennium's multiple myeloma agent Velcade is leading the parade of oncologic therapies attracting renewed enthusiasms from investors

Related Content

UsernamePublicRestriction

Register

PS041397

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel